Daniel S. Lieber
Foundation Medicine (United States) · 49 works · 6,826 citations · h-index 15
Top works
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- Molecular Diagnosis of Infantile Mitochondrial Disease with Targeted Next-Generation Sequencing
- Global and Local Architecture of the Mammalian microRNA–Transcription Factor Regulatory Network
- Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
- Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
- Targeted exome sequencing of suspected mitochondrial disorders
- Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)
- Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST)
- Atypical case of Wolfram syndrome revealed through targeted exome sequencing in a patient with suspected mitochondrial disease
- Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency
- Macrocytic Anemia and Mitochondriopathy Resulting from a Defect in Sideroflexin 4
- Large-Scale Discovery and Characterization of Protein Regulatory Motifs in Eukaryotes
- The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
- Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab
- Abstract 2987: Validation and clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB)
- Orthogonal NGS for High Throughput Clinical Diagnostics
- Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)
- Abstract B16: Validation and clinical feasibility of a Foundation Medicine assay to identify immunotherapy response potential through tumor mutational burden (TMB)
- Computational and Experimental Approaches For Evaluating the Genetic Basis of Mitochondrial Disorders